Neuronetics (STIM) reported a net loss of 33 cents per share in second-quarter 2024, wider than the year-ago quarter's reported loss of 17 cents. The figure also lagged the Zacks Consensus Estimate of a loss of 27 cents per share. Q2 Revenues Consolidated revenues amounted to $16.5 million, down 6.3% from $17.6 million recorded in the second quarter of 2023. The figure missed the Zacks Consensus Estimate by 12.2%. Segments in Detail Neuronetics reports under two primary markets, based on the geographic loca ...

Exhibit 99.1 Presentation Operator Good day, and thank you for standing by. Welcome to the Neuronetics Second Quarter 2024 Financial and Operating Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to Mark Klausner. Please go ahead. Mark R. Klausner Westwicke Partners, LLC Good morning, and thank you for joining us for the Neuronetics Second Quarter 2024 Conference Call. Joining me on today's call are Neu ...

Neuronetics, Inc. (NASDAQ:STIM) Q2 2024 Earnings Conference Call August 12, 2024 8:30 AM ET Company Participants Keith Sullivan - President & CEO Steve Furlong - CFO Mark Klausner - IR Conference Call Participants Margaret Andrew - William Blair Adam Maeder - Piper Sandler John Pinney - Canaccord Genuity Danny Stauder - Citizens JMP Operator Good day, and thank you for standing by. Welcome to the Neuronetics second quarter 2024 financial and operating results conference call. [Operator Instructions]. Please ...

On Monday, Neuronetics Inc. STIM, a provider of noninvasive treatments for psychiatric disorders, agreed to acquire Greenbrook TMS Inc. GBNHF in an all-stock transaction. In fiscal year 2023, the combined company's pro forma revenue would have been approximately $145 million, effectively doubling the scale of the stand-alone businesses. Additionally, the combined company expects mid-teens year-over-year revenue growth in fiscal years 2025 and 2026. Through optimizing marketing spend and back office function ...

Advanced Therapy for Mental Health 2Q 2024 Earnings August 12, 2024 Forward Looking Statements This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data. Certain statements in this pres ...

Neuronetics (STIM) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -22.22%. A quarter ago, it was expected that this medical device company focused on psychiatric disorders would post a loss of $0.33 per share when it actually produced a loss of $0.27, delivering a surprise of 18.18%. Over t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ | --- | --- | --- | |-----------------------------------------------------------------------------------|----------------- ...

MALVERN, Pa. and TORONTO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTCMKTS: GBNHF) ("Greenbrook") today announced that they have entered into a definitive arrangement agreement (the "Definitive Agreement") in which Neuronetics will acquire all of the outstanding common shares of Greenbrook in an all-stock transaction. "This transaction brings together two of the leaders in the mental health space in the U.S., which will allow us to provide a ...

MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the second quarter of 2024. Second Quarter 2024 Highlights Second quarter 2024 revenue of $16.5 million, a 7% decrease as compared to the second q ...

About Neuronetics | --- | |---------------------------------| | | | Mike Vallie or Mark Klausner | | ICR Westwicke | | 443-213-0499 ir@neuronetics.com | | Media Contact: | | EvolveMKD | | 646-517-4220 | | NeuroStar@evolvemkd.com | A live audio webcast of the presentation will be available online at the investor relations page of the Company's website at ir.neuronetics.com. Investor Contact: MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused ...